Near normalization of adult height and body proportions by growth hormone in pycnodysostosis
- PMID: 20357177
- DOI: 10.1210/jc.2009-2531
Near normalization of adult height and body proportions by growth hormone in pycnodysostosis
Abstract
Context: Mutations in the cathepsin K gene (CTSK) cause a very rare form of short-limb dwarfism called pyknodysostosis (online inheritance in man 265800) that reduces adult height to 130-150 cm.
Objective: To study the effects of GH in children with pyknodysostosis.
Design and methods: This was a pilot open study of three children with pyknodysostosis (P1, P2, P3) and 16 age-matched children with idiopathic short stature (ISS) treated with a similar IGF-I-based dosing of GH therapy. P1, P2, and P3 received a mean GH dose of 29, 67, and 120 microg/kg x d, respectively, during 12, 6.5, and 5 yr, whereas the ISS group received a mean dose of 62 +/- 21 microg/kg x d during 5.4 +/- 2 yr.
Results: P1, P2, and P3 had the typical clinical and radiological features of pyknodysostosis. They were shown to carry three different homozygous missense mutations of the CTSK gene. After onset of GH at 4.5, 5.4, and 10.9 yr of age, respectively, height increased from -2, -4.2, and -3 SD score to -1, -0.5, and -1 SD score after a 12, 6.5, and 5 yr GH treatment. Remarkably, body disproportion was largely corrected by GH treatment. IGF-I levels in P1, P2, and P3 were within the range of the ISS group.
Conclusions: Pyknodysostotic patients can reach near-normal stature and skeletal proportions with a personalized GH treatment targeted at appropriate IGF-I levels. Given the severity of this rare dwarfism, we propose that GH should be offered to affected children.
Similar articles
-
Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.J Clin Endocrinol Metab. 2010 May;95(5):2089-98. doi: 10.1210/jc.2009-2139. Epub 2010 Mar 5. J Clin Endocrinol Metab. 2010. PMID: 20207829 Clinical Trial.
-
High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.J Clin Endocrinol Metab. 2000 Oct;85(10):3653-60. doi: 10.1210/jcem.85.10.6906. J Clin Endocrinol Metab. 2000. PMID: 11061518 Clinical Trial.
-
A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation.J Clin Endocrinol Metab. 2001 Jul;86(7):2969-75. doi: 10.1210/jcem.86.7.7650. J Clin Endocrinol Metab. 2001. PMID: 11443153 Clinical Trial.
-
Principles of growth hormone and insulin-like growth factor-I treatment in children with idiopathic short stature.Horm Res Paediatr. 2011;76 Suppl 3:24-6. doi: 10.1159/000330148. Epub 2011 Sep 7. Horm Res Paediatr. 2011. PMID: 21912155 Review.
-
Is GH therapy useful to preserve bone mass in transition-phase patients with GH deficiency?J Endocrinol Invest. 2005;28(10 Suppl):28-32. J Endocrinol Invest. 2005. PMID: 16550719 Review.
Cited by
-
Growth hormone treatment improves final height in children with X-linked hypophosphatemia.Orphanet J Rare Dis. 2022 Dec 21;17(1):444. doi: 10.1186/s13023-022-02590-5. Orphanet J Rare Dis. 2022. PMID: 36544157 Free PMC article.
-
Management of long bone fractures in patients with pycnodysostosis.BMJ Case Rep. 2023 Sep 18;16(9):e252667. doi: 10.1136/bcr-2022-252667. BMJ Case Rep. 2023. PMID: 37723084
-
A Case Report of Pycnodysostosis Associated with Multiple Pituitary Hormone Deficiencies and Response to Treatment.J Clin Res Pediatr Endocrinol. 2020 Nov 25;12(4):444-449. doi: 10.4274/jcrpe.galenos.2020.2019.0194. Epub 2020 Apr 6. J Clin Res Pediatr Endocrinol. 2020. PMID: 32248673 Free PMC article.
-
Genetic study of eight Egyptian patients with pycnodysostosis: identification of novel CTSK mutations and founder effect.Osteoporos Int. 2018 Aug;29(8):1833-1841. doi: 10.1007/s00198-018-4555-0. Epub 2018 May 23. Osteoporos Int. 2018. PMID: 29796728
-
Cathepsin K Mutation-A Subtle Clinical Presentation.J Endocr Soc. 2022 Jul 5;6(8):bvac102. doi: 10.1210/jendso/bvac102. eCollection 2022 Aug 1. J Endocr Soc. 2022. PMID: 35854980 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
